117 related articles for article (PubMed ID: 37914140)
1. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells.
Che PP; Gregori A; Bergonzini C; Ali M; Mantini G; Schmidt T; Finamore F; Rodrigues SMF; Frampton AE; McDonnell LA; Danen EH; Slotman BJ; Sminia P; Giovannetti E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1328-1343. PubMed ID: 37914140
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
[TBL] [Abstract][Full Text] [Related]
3. ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Chakraborty A; Dorsett KA; Trummell HQ; Yang ES; Oliver PG; Bonner JA; Buchsbaum DJ; Bellis SL
J Biol Chem; 2018 Jan; 293(3):984-994. PubMed ID: 29191829
[TBL] [Abstract][Full Text] [Related]
4. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
[TBL] [Abstract][Full Text] [Related]
5. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells.
Bergonzini C; Gregori A; Hagens TMS; van der Noord VE; van de Water B; Zweemer AJM; Coban B; Capula M; Mantini G; Botto A; Finamore F; Garajova I; McDonnell LA; Schmidt T; Giovannetti E; Danen EHJ
J Exp Clin Cancer Res; 2024 Jan; 43(1):4. PubMed ID: 38163893
[TBL] [Abstract][Full Text] [Related]
7. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
8. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
9. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
10. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
11. Matrix stiffness triggers chemoresistance through elevated autophagy in pancreatic ductal adenocarcinoma.
Pan H; Zhu S; Gong T; Wu D; Zhao Y; Yan J; Dai C; Huang Y; Yang Y; Guo Y
Biomater Sci; 2023 Nov; 11(22):7358-7372. PubMed ID: 37781974
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
[TBL] [Abstract][Full Text] [Related]
13. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
14. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
15. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
18. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
19. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
20. Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Amrutkar M; Aasrum M; Verbeke CS; Gladhaug IP
BMC Cancer; 2019 Jun; 19(1):596. PubMed ID: 31208372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
